• 1
    Schuppan D, Stölzel U, Oesterling C, Somasundaram R. Serum assays for liver fibrosis. J Hepatol 1995; 22 (suppl 2): 82S88S.
  • 2
    Schuppan D, Aksü T, Libuda P, Herbst H. Serum markers for liver fibrosis–current and future developments. In: ReichenJ, PouponR, eds. Surrogate Markers for Liver Diseases. Dordrecht: Kluwer, 1996: 105122.
  • 3
    Gerling B, Becker M, Waldschmidt J, Schuppan D. Elevated serum aminoterminal procollagen type III peptide parallels collagen accumulation in rats with secondary biliary fibrosis. J Hepatol 1996; 25: 7984.
  • 4
    Leng–Peschlow E, Strenge–Hesse A. Die Mariendistel (Silybum mari–anum) und Silymarin als Lebertherapeutikum. Z Phytother 1991; 12: 162174.
  • 5
    Frimmer VM, Kroker R. Phalloidine antagonists: 1. Effects of silybine derivates on isolated perfused rat liver. Arzneim Forsch 1975; 25: 394396.
  • 6
    Faulstich H, Jahn W, Wieland T. Silibinin inhibition of amatoxin uptake in the perfused rat liver. Arzneim Forsch 1980; 30: 452454.
  • 7
    Machicao F, Sonnenbichler J. Mechanism of the stimulation of RNA synthesis in rat liver nuclei by silibinin. Hoppe–Seyler's Z Physiol Chem 1977; 358: 141147.
  • 8
    Sonnenbichler J, Zetl I. Untersuchungen zum Wirkungsmechanismus von Silibinin. V. Einfluss auf die Synthese ribosomaler RNA, mRNA und tRNA in Rattenlebern in vivo. Hoppe–Seyler's Z Physiol Chem 1984; 365: 555566.
  • 9
    Mira I, Silva M, Manso CF. Scavenging of reactive oxygen species by silibinin dihemisuccinate. Biochem Pharmacol 1994; 48: 753759.
  • 10
    Mourelle M, Muriel P, Favari L, Franco T. Prevention of CC14–induced liver cirrhosis by silymarin. Fundam Clin Pharmacol 1989; 3: 183191.
  • 11
    Muriel P, Mourelle M Prevention by silymarin of membrane alterations in acute CCl4 liver damage. J Appl Toxicol 1990; 10: 275279.
  • 12
    Muriel P, Garciapina T, Perez-Alvarez V, Mourelle M. Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. J Appl Toxicol 1992; 12: 439442.
  • 13
    Valenzuela A, Lagos C, Schmidt K, Videla LA. Silymarin protects against hepatic lipid peroxidation induced by acute ethanol intoxication in the rat. Biochem Pharmacol 1985; 34: 22092212.
  • 14
    Bosiso E, Benelli C, Pirola O. Effect of the flavonolignans of Silybum marianurn L. on lipid peroxidation in rat liver microsomes and freshly isolated hepatocytes. Pharmacol Res 1992; 25: 147154.
  • 15
    Sonnenbichler J, Goldberg M, Hane L, Madubunyi I, Vogel S, Zetl I. Stimulatory effect of silibinin on the DNA synthesis in partially hepatec-tomized rat livers: non-response in hepatoma and other malignant cell lines. Biochem Pharmacol 1986; 35: 538541.
  • 16
    Agarwal R, Katiyar SK, Lundgren DW, Mukhtar H. Inhibitory effect of silymarin, an anti-hepatotxic flavonoid, on 12-O-tetradecanoylphorbol-13-acetate-induced epidermal ornithine decarboxylase and mRNA in SENCARmice. Carcinogenesis 1994; 15: 10991103.
  • 17
    Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, Meryn S, Base W, Schneider B. Randomized controlled trial of silymarin-treat-ment in patients with cirrhosis of the liver. J Hepatol 1989; 9: 105113.
  • 18
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431435.
  • 19
    Ruwart MJ, Wilkinson KF, Rush BD, et al. The integrated value of serum procollagen III peptide over time predicts hepatic hydroxyproline content and stainable collagen in a model of dietary cirrhosis in the rat. Hepatology 1989; 10: 801806.
  • 20
    Jamall IS, Finelli VN, Que Hee SS. A simple method to determine nano-gram levels of 4-hydroxyproline in biological tissues. Ann Biochem 1981; 112: 7075.
  • 21
    Schuppan D, Dumont JM, Kim KY, Hennings G, Hahn EG. Serum concentration of the aminoterminal procollagen III peptide in the rat reflects early formation of connective tissue in experimental liver cirrhosis. J Hepatol 1986; 3: 2737.
  • 22
    Vogel G, Trost W, Braatz R, Odenthal KP, Brüsewitz G, Antweiler H, Seeger R. Untersuchungen zu Pharmakodynamik, Angriffspunkt und Wirkungsmechanismus von Silymarin, dem antihepatotoxischen Prin-zip aus Silybum marianum L. Gaertn. Arzneim Forsch 1975; 25: 179188.
  • 23
    Bülles H, Bülles J, Krumbiegel G, Mennicke WH, Nitz D. Untersuchungen zur Verstoffwechselung und zur Ausscheidung von Silybin bei der Ratte. Arzneim Forsch 1975; 25: 902905.
  • 24
    Gressner AM. Hepatic fibrogenesis: the puzzle of interacting cells, fibro-genic cytokines, regulatory loops, and extracellular matrix molecules. Z Gastroenterol 1992; 30 (suppl 1): 5S16S.
  • 25
    Schuppan D, Herbst H, Milani S. Matrix, matrix synthesis and molecular networks. In: ZernMA, ReidLM, eds. Extracellular Matrix: Chemistry, Biology and Pathobiology With Emphasis on the Liver. New York: Marcel Dekker, 1993: 201254.
  • 26
    Friedman SL. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993; 328: 18281835.
  • 27
    Fuchs EC, Gressner AM, Weyhenmeyer R, Weiner OH. Identification of the antifibrogenic properties of silibinin: effect on TGF-β and matrix gene expression of hepatic stellate cells [Abstract]. Hepatology 1995; 22: 286A.
  • 28
    Dehmlow C, Erhard J, De Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 1996; 23: 749754.
  • 29
    Hagman W. The liver in leukotriene action, metabolism, and production: physiologic and pathophysiologic conditions. In: MatuschakGM, ed. Multiple Systems Organ Failure. New York: Marcel Dekker, 1990: 165191.
  • 30
    Britton RS, Bacon BR. Role of free radicals in liver diseases and hepatic fibrosis. Hepatogastroenterology 1994; 41: 343348.
  • 31
    Tanner MS, Jackson D, Mowat AP. Hepatic collagen synthesis in a rat model of cirrhosis, and its modification by colchicine. J Pathol 1981; 135: 179187.
  • 32
    Dumont JM, Maignan MF, Janin B, Herbage D, Perrissoud D. Effect of malotilate on chronic liver injury induced by carbon tetrachloride in the rat. J Hepatol 1986; 3: 260268.
  • 33
    Senoo H, Wake K. Suppression of experimental hepatic fibrosis by administration of vitamin A. Lab Invest 1985; 52: 182194.
  • 34
    Seifert WF, Bosma A, Brouwer A, Hendriks HF, Roholl PJ, van Leeuwen RE, van Thiel de Ruiter GC, et al. Vitamin A deficiency potentiates carbon tetrachloride-induced liver fibrosis in rats. Hepatology 1994; 19: 193201.
  • 35
    Parola M, Muraca R, Dianzani I, Barrera G, Leonarduzzi G, Bendinelli P, Piccoletti R, et al. Vitamin E dietary supplementation inhibits transforming growth factor beta 1 gene expression in the rat liver. FEBS Lett 1992; 308: 267270.
  • 36
    McCay PB, Brueggemann G, Lai EK, Powell SR. Evidence that alpha-tocopherol functions cyclically to quench free radicals in hepatic micro-somes. Requirement for glutathione and a heat-labile factor. Ann N Y Acad Sci 1989; 570: 3245.
  • 37
    Liu SL, Esposti S Degli, Yao T, Diehl AM, Zern MA. Vitamin E therapy of acute CCl4-induced hepatic injury in mice is associated with inhibition of nuclear factor kappa B binding. Hepatology 1995; 22: 14741481.
  • 38
    Schuppan D, Kim KY, Riecken EO. Antifibrogenic effect of ursodeoxy-cholic acid, cyclosporin A, penicillamin, prednisolone and colchicine in a rat model of secondary biliary fibrosis [Abstract]. Hepatology 1989; 10: 630A.